Current data on Covid-19 vaccine in pediatrics

Abstract

To date, COVID-19 has infected more than 200 million people worldwide, with 4 million having died because of it. The infection rate among pediatrics was 14.2% of the total COVID-19 cases. One of the effective tools for stopping this pandemic is the provision of SARS-CoV-2 immunity via vaccination. Many platforms have been developed in efforts to make the best SARS-CoV-2 vaccine. Most clinical studies confirmed their safety and efficacy in adults. However, we cannot guarantee that the immunogenicity and safety results of vaccines against SARS-CoV-2 in adults are the same for children. There are only 3 studies on the use of SARS-CoV-2 vaccines in children. Two mRNA-based vaccines have been approved for emergency use in children aged 12 years or older. The Pfizer-BioNTech COVID-19 vaccine, an mRNA-based vaccine, was the first COVID-19 vaccine authorized by the U.S. Food and Drug Administration for the prevention of COVID-19 disease in people aged 16 and older. In addition, 2 inactivated vaccines have been approved for use on children as young as 3 years of age. To date, 4 SARS-CoV-2 vaccines have been approved for use in children. However, data on the efficacy and safety of SARSCoV-2 vaccines in children under 12 years of age are scarce. Studies on the long-term safety of the use of these vaccines in children is urgently needed. [ FROM AUTHOR] Copyright of Pharmaceutical Sciences Asia is the property of Mahidol University, Faculty of Pharmacy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)